Complete Genomics, Inc., a pioneering genomics company, today unveiled updated mission/vision statement to reflect renewed ambitions in taking on more for a better world, in celebration of its 18 th ...

Complete Genomics and Velsera are collaborating to deliver an end-to-end genetic testing solution that integrates DNBSEQ™ sequencing technology with Velsera’s Clinical Genomics Workspace (CGW) data ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Radoje Drmanac received a Ph.D. in molecular biology from ...

Complete Genomics performs whole human genome sequencing using proprietary biochemistry based on DNA nanoball arrays and combinatorial probe-anchor ligation sequencing. As these methods1 produce reads ...

The board of Complete Genomics has recommended that its shareholders accept a $117.6 million takeover bid by China’s BGI-Shengzhen. Under terms of the agreement, a wholly owned U.S. subsidiary of ...

SAN JOSE, Calif. and MARCO ISLAND, Fla., Feb. 24, 2026 /PRNewswire/ -- Complete Genomics, a U.S.-based, innovator in genomic sequencing platforms and solutions, today announced it is commencing ...

Complete Genomics Inc., a global life science tools leader and subsidiary of MGI Tech Co., Ltd. (“MGI”), today launched new revolutionary products and prices at Advances in Genome Biology and ...

Sells sequencing as a service, analyzing DNA samples that customers send in. Technology: Complete Genomics makes machines that can sequence whole human genomes quickly and cheaply, thanks in part to a ...

SAN JOSE, Calif., June 9, 2026 /PRNewswire/ -- Complete Genomics today announced the appointment of Edward T. McMullen Jr. to its Board of Directors, further strengthening the company's leadership in ...

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (SOPH) (Nasdaq: SOPH), a global leader in ...

With confidence dropping in doing business with China-affiliated life sciences companies due to the Biosecure Act, one of the companies explicitly named in the U.S. legislation is fighting back.

DNBSEQ-T20×2*produces up to 50,000 WGS per year at a first sub hundred-dollar price per genome DNBSEQ-T7* offers an outstanding $1.5/Gb price for sequencing consumables DNBSEQ-G99* delivers a first-in ...